RxDoctor Payments Data

John Katsaropoulos, MD

Interventional Cardiology · Indianapolis, INNPI 1063419968

Payments from drug & device makers

$2,212in general payments, 2019–2025

Across 81 payments — averaging $27.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$990
  • Novartis$306
  • Medtronic$172
  • Abiomed$136
  • Biotronik Inc.$118
  • Heartflow, Inc.$104
  • plus $387 from 12 others

What the payments were for

  • Food & beverage$2,212100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,212 in reported general payments places this provider in the 15th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$67,688
Medicare patients
278
Services billed
590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$130,245
XareltoRivaroxaban30$43,704
EntrestoSacubitril/Valsartan30$34,713
Repatha SureclickEvolocumab18$19,792
BrilintaTicagrelor20$14,577
Praluent PenAlirocumab12$10,180
Atorvastatin Calcium394$3,123
Ranolazine ErRanolazine23$2,162
Ezetimibe100$2,075
ClopidogrelClopidogrel Bisulfate202$1,882
Rosuvastatin Calcium123$1,613
Metoprolol Succinate133$1,537
Losartan Potassium102$1,251
Metoprolol Tartrate191$1,011
Isosorbide Mononitrate ErIsosorbide Mononitrate114$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$306$34,71330 claims
AstraZenecaBrilinta$13$14,57720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →